首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2017年 5期中西医结合肝胆胰疾病 => 专家论坛 =>中医药抗肝纤维化疗效..
中医药抗肝纤维化疗效评价的探索
An exploration of therapeutic evaluation of traditional Chinese medicine in treatment of hepatic fibrosis
文章发布日期:2017年04月06日  来源:  作者:徐列明  点击次数:2007次  下载次数:363次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:我国在利用中成药治疗肝纤维化方面已走在国际前列。建议从抗肝纤维化的近期疗效、长期疗效和症状改善疗效3个方面开展评价,并介绍了笔者探索应用肝脏弹性测量值评价中成药抗纤维化的临床疗效,以5年生存率评价长期疗效,以及采用“中医证候评定量表”评价症状改善疗效的实践结果,显示出中成药扶正化瘀胶囊/片抗肝纤维化的临床疗效显著。建议配合血清学诊断模型,开展前瞻性的长期随访和对长期积累的大样本、大数据作分析,以完善抗肝纤维化疗效评价方法。
【Abstract】:China has become one of the leading counties in the world to treat hepatic fibrosis with Chinese patent drugs. The therapeutic effect of traditional Chinese medicine (TCM) should be evaluated from the aspects of short-term therapeutic effect, long-term therapeutic effect, and effect of relief of symptoms. This article introduces the results of our exploration of the application of liver stiffness measurement to evaluate therapeutic effect, five-year survival rate to assess long-term therapeutic effect, and a “TCM syndrome scale” to evaluate effect of relief of symptoms, suggesting that the Chinese patent drug Fuzheng Huayu capsules/tablets have a marked clinical effect in the treatment of hepatic fibrosis. It is recommended to use serological diagnostic models, conduct prospective studies with long-term follow-up, and analyze the samples and data accumulated over a long period of time, in order to perfect the methods for evaluating the outcome of hepatic fibrosis.
【关键字】:肝硬化; 中成药; 治疗结果
【Key words】:liver cirrhosis; Chinese patent drugs; treatment outcome
【引证本文】:徐列明. 中医药抗肝纤维化疗效评价的探索[J]. 临床肝胆病杂志, 2017, 33(5): 825-828.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号